Home Ingredients Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues)
CognitiveAnti-InflammatoryLiver HealthJoint Health

Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues)

Curcuma longa L. (curcumin nanoparticle dispersion)
Evidence Level
Moderate
3 Clinical Trials
7 Documented Benefits
3/5 Evidence Score

Branded high-bioavailability curcumin from Theravalues Corporation (Tokyo, Japan) — formulated as a colloidal nanoparticle dispersion that provides 27-fold higher blood concentration AUC vs standard curcumin powder in the same volunteers. Small 2014 (PMID 29246725, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010) is the pivotal 18-month UCLA cognitive RCT in non-demented adults aged 50-90 — memory, attention, and mood improvements with FDDNP-PET amyloid plaque and tau tangle imaging. NCT07251985 — UCLA Phase 2 12-month cognitive trial currently planned. NAFLD and hemodialysis hs-CRP reduction trials positive. Honest counter-evidence: COPD 24-week and CSFP trials were NEGATIVE on hs-CRP — anti-inflammatory effects appear condition-dependent, not universal.

Studied Dose SMALL 2014 PIVOTAL: 90 mg twice daily = 180 mg/day × 18 months. UCLA NCT07251985: 75 mg/day × 12 months. NAFLD: 80 mg/day × 3 months. HEMODIALYSIS: 120 mg/day × 12 weeks. Standard range: 30-180 mg/day. 27× bioavailability advantage means much lower dose than standard curcumin (1-2 g).
Active Compound Curcumin (diferuloylmethane) dispersed with colloidal nanoparticles via Theravalues' patented manufacturing process. INCREASED INTESTINAL ENDOTHELIUM PENETRABILITY due to nanoparticle dispersion. 27× higher blood concentration AUC vs standard curcumin powder

Benefits

Cognitive function, memory, mood — 18-month RCT (Small 2014 PIVOTAL)

Small GW et al. 2014 (PMID 29246725, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010) — randomized double-blind placebo-controlled trial in middle-aged and older non-demented adults aged 50-90 with mild memory complaints. Theracurmin® 90 mg twice daily (180 mg/day) vs placebo for 18 months. Memory, attention, and mood improvements. FDDNP-PET imaging documented changes in brain amyloid plaque and tau tangle deposition. UCLA Gary Small lead investigator. Longest cognitive curcumin trial to date with mechanistic neuroimaging.

Supported by Trial 1

MCI and Alzheimer's stabilization 6-month trial (Theravalues)

Theravalues 6-month MCI/AD stabilization trial (n=93). Showed non-treated decline vs Theracurmin-treated stabilization in MoCA, ADL, and MMSE assessments. Industry-sponsored trial — supports the longer-term Small 2014 cognitive findings in a higher-impairment population.

Supported by Trial 2

UCLA 12-month Phase 2 cognitive trial (NCT07251985)

NCT07251985 — UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day. Currently in not-yet-recruiting status. Continued academic research interest beyond the manufacturer — supports beyond-industry credibility.

Supported by Trial 3

NAFLD 3-month RCT — hs-CRP reduction

Iranian NAFLD 3-month RCT at 80 mg/day Theracurmin reduced hs-CRP (high-sensitivity C-reactive protein). Anti-inflammatory effect in fatty liver disease population — relevant to the broader NAFLD intervention landscape where pharmacological options are limited.

Supported by Trial 1, Trial 3

Hemodialysis 12-week RCT — hs-CRP reduction

Iranian hemodialysis 12-week RCT at 120 mg/day Theracurmin reduced hs-CRP in chronic kidney disease patients on dialysis. Anti-inflammatory effect in a chronic-inflammation population.

Supported by Trial 1, Trial 3

27-fold bioavailability advantage vs standard curcumin

Healthy human volunteers consuming 30 mg oral Theracurmin show 27-fold higher area under the blood concentration-time curve compared to the same volunteers consuming standard curcumin powder. 30 mg Theracurmin ≈ 810 mg standard curcumin equivalent. Genuine pharmacokinetic advantage supported by independent published research.

Supported by Trial 1, Trial 3

Honest counter-evidence — condition-dependent anti-inflammatory

COPD 24-week trial at 180 mg/day did NOT improve hs-CRP. CSFP (coronary slow flow phenomenon) trial PMC11290174 also did not improve hs-CRP. Anti-inflammatory effects are condition-dependent rather than universal. The cognitive and NAFLD/hemodialysis evidence does not generalize to all inflammatory conditions — important framing against blanket anti-inflammatory marketing claims.

Supported by Trial 1, Trial 3

Mechanism of action

1

Colloidal nanoparticle dispersion (distinguishing pharmacokinetics)

Curcumin (diferuloylmethane) is dispersed with colloidal nanoparticles via Theravalues' proprietary manufacturing process. The nanoparticle form enables intestinal endothelium penetration that standard crystalline curcumin (poorly water-soluble) cannot achieve. Distinct from phytosome (Meriva), micellar (Longvida), curcumin-piperine (BCM-95), curcumin-fenugreek (CurQfen), and other curcumin formulations.

2

Increased intestinal endothelium penetrability

Nanoparticle dispersion enables passage through the intestinal endothelium that standard crystalline curcumin cannot achieve due to poor water solubility. The pharmacokinetic basis for the 27× AUC improvement.

3

NF-κB anti-inflammatory pathway suppression

Curcumin's core anti-inflammatory mechanism via NF-κB pathway suppression. Bioavailable Theracurmin reaches systemic concentrations supporting clinical activity that standard curcumin cannot at comparable doses.

4

BBB penetration with bioavailable form

The bioavailable nanoparticle form enables blood-brain barrier penetration and central nervous system effects underlying the cognitive benefits. Standard curcumin's poor bioavailability limits CNS exposure.

5

Amyloid plaque and tau tangle modulation

Small 2014 documented FDDNP-PET imaging changes in brain amyloid plaque and tau tangle deposition — the proposed disease-relevant mechanism underlying the cognitive benefits in non-demented older adults.

6

Antioxidant via direct ROS scavenging and Nrf2 activation

Direct ROS scavenging plus Nrf2 pathway activation — standard curcumin antioxidant mechanisms now achievable at lower doses due to enhanced bioavailability.

Clinical trials

1
Small 2014 — Theracurmin 18-Month Cognitive RCT (PIVOTAL)

Small GW et al. 2014 (PMID 29246725, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010). Randomized double-blind placebo-controlled trial in non-demented adults aged 50-90 with mild memory complaints. Theracurmin® 90 mg twice daily (180 mg/day) vs placebo for 18 months. Memory, attention, and mood improvements. FDDNP-PET imaging changes in brain amyloid plaque and tau tangle deposition. UCLA Gary Small lead investigator. The longest cognitive curcumin trial to date.

2
Theravalues Study #4 — MCI/AD 6-Month Stabilization Trial

Theravalues 6-month MCI/AD stabilization trial (n=93). Non-treated decline vs Theracurmin-treated stabilization in MoCA, ADL, and MMSE. Industry-sponsored — supports Small 2014 cognitive findings in a higher-impairment population.

3
NCT07251985 — UCLA 12-Month Phase 2 Cognitive Trial (Planned)

UCLA-sponsored Phase 2 12-month cognitive trial using Theracurmin Super TS-P1 75 mg/day. Currently in not-yet-recruiting status. Ongoing academic research interest beyond the manufacturer.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; 18-month Small 2014 trial supports long-term safety.
Mild GI upset (rare).
Possible mild yellow staining of skin/clothes (cosmetic only).
Pregnancy/lactation: AVOID (limited data, theoretical uterine effects of curcumin).
Bleeding disorders: theoretical mild antiplatelet effect — caution.
Gallbladder disease: theoretical caution (curcumin stimulates bile production).
Long-term safety: 18-month trial confirms favorable profile.

Important Drug interactions

Anticoagulants (warfarin, DOACs): theoretical mild antiplatelet effect — monitor.
Antidiabetic medications: theoretical compatible/additive glucose effects.
NSAIDs: COMPATIBLE; complementary anti-inflammatory mechanism.
CYP3A4 substrates: theoretical interactions (via curcumin CYP3A4 inhibition).
Iron supplements: theoretical reduced iron absorption — separate by 2 hours.
Most medications: well-tolerated combination profile.

More Cognitive Ingredients

Athletic Performance
Creatine Monohydrate
A nitrogen-containing organic acid synthesized in the liver and kidney from arginine, glyc…
Cognitive
Vitamin B12
Vitamin B12, also known as cobalamin, is a water-soluble vitamin commonly supplemented as…
Eye Health
FloraGLO® Lutein (Kemin)
FloraGLO® is a branded free-form lutein extract manufactured by Kemin Industries from mari…
Cardiovascular
Fish Oil (EPA + DHA)
Oil extracted from oily fish (anchovy, sardine, mackerel, herring, salmon) — the most stud…

Explore Other Ingredients

Immune Support
Andrographis (ParActin®)
Andrographis paniculata (King of Bitters) is a bitter herb native to South and Southeast A…
Joint Health
AprèsFlex® / Aflapin® (Boswellia AKBA — Laila Nutraceuticals)
Branded enhanced bioavailability Boswellia serrata extract from Laila Nutraceuticals (Indi…
Joint Health
GOPO® Rosehip (Hyben Vital — Rosa canina)
Branded standardized rosehip powder from Hyben Vital International (Denmark — Tullebølle,…

Frequently asked questions about Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues)

What is the recommended dosage of Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues)?

The clinically studied dose for Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) is SMALL 2014 PIVOTAL: 90 mg twice daily = 180 mg/day × 18 months. UCLA NCT07251985: 75 mg/day × 12 months. NAFLD: 80 mg/day × 3 months. HEMODIALYSIS: 120 mg/day × 12 weeks. Standard range: 30-180 mg/day. 27× bioavailability advantage means much lower dose than standard curcumin (1-2 g).. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) used for?

Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) is studied for cognitive function, memory, mood — 18-month rct (small 2014 pivotal), mci and alzheimer's stabilization 6-month trial (theravalues), ucla 12-month phase 2 cognitive trial (nct07251985). Small GW et al. 2014 (PMID 29246725, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010) — randomized double-blind placebo-controlled trial in middle-aged and older non-demented adults aged 50-90 with mild memory complaints.

Are there side effects from taking Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues)?

Reported potential side effects may include: Generally well-tolerated; 18-month Small 2014 trial supports long-term safety. Mild GI upset (rare). Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) interact with medications?

Known drug interactions may include: Anticoagulants (warfarin, DOACs): theoretical mild antiplatelet effect — monitor. Antidiabetic medications: theoretical compatible/additive glucose effects. Consult a pharmacist or healthcare provider if you take prescription medications.

Is Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) good for cognitive?

Yes, Theracurmin® (Colloidal Nanoparticle Curcumin — Theravalues) is researched for Cognitive support. Small GW et al. 2014 (PMID 29246725, Am J Geriatr Psychiatry, doi:10.1016/j.jagp.2017.10.010) — randomized double-blind placebo-controlled trial in middle-aged and older non-demented adults aged 50-90 with mild memory complaints.